The funding will also cover medicines for other conditions, totalling up to an estimated 54 new or widened access medicines. The next step for Pharmac involves working through the medicines on its Options for Investment (OFI) list to determine which medicines to progress. It will then begin negotiating with suppliers, and consulting publicly.
This is a companion discussion topic for the original entry at https://www.sciencemediacentre.co.nz/2024/06/24/extra-600m-to-fund-cancer-meds-and-other-treatments-expert-reaction/